These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8817161)

  • 21. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial.
    Montaner JS; Singer J; Schechter MT; Raboud JM; Tsoukas C; O'Shaughnessy M; Ruedy J; Nagai K; Salomon H; Spira B
    AIDS; 1993 Feb; 7(2):189-96. PubMed ID: 8466681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase.
    Yahi N; Tamalet C; Tourrès C; Tivoli N; Fantini J
    J Biomed Sci; 2000; 7(6):507-13. PubMed ID: 11060499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.
    Eastman PS; Urdea M; Besemer D; Stempien M; Kolberg J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):264-73. PubMed ID: 7540490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.
    Sharma PL; Chatis PA; Dogon AL; Mayers DL; McCutchan FE; Page C; Crumpacker CS
    Virology; 1996 Sep; 223(2):365-9. PubMed ID: 8806572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
    Miller V; Ait-Khaled M; Stone C; Griffin P; Mesogiti D; Cutrell A; Harrigan R; Staszewski S; Katlama C; Pearce G; Tisdale M
    AIDS; 2000 Jan; 14(2):163-71. PubMed ID: 10708287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy.
    Loveday C; Kaye S; Tenant-Flowers M; Semple M; Ayliffe U; Weller IV; Tedder RS
    Lancet; 1995 Apr; 345(8953):820-4. PubMed ID: 7534858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.
    Japour AJ; Welles S; D'Aquila RT; Johnson VA; Richman DD; Coombs RW; Reichelderfer PS; Kahn JO; Crumpacker CS; Kuritzkes DR
    J Infect Dis; 1995 May; 171(5):1172-9. PubMed ID: 7538548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
    Kojima E; Shirasaka T; Anderson BD; Chokekijchai S; Steinberg SM; Broder S; Yarchoan R; Mitsuya H
    J Infect Dis; 1995 May; 171(5):1152-8. PubMed ID: 7751690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.
    Welles SL; Pitt J; Colgrove R; McIntosh K; Chung PH; Colson A; Lockman S; Fowler MG; Hanson C; Landesman S; Moye J; Rich KC; Zorrilla C; Japour AJ
    AIDS; 2000 Feb; 14(3):263-71. PubMed ID: 10716502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (codon 215) and didanosine (codon 74). Division of AIDS Treatment Research Initiative 003 Study Group.
    Mayers D; Bethel J; Wainberg MA; Weislow O; Schnittman S
    J Infect Dis; 1998 Jun; 177(6):1730-3. PubMed ID: 9607859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.
    Staszewski S; Miller V; Rehmet S; Stark T; De Crée J; De Brabander M; Peeters M; Andries K; Moeremans M; De Raeymaeker M; Pearce G; Van den Broeck R; Verbiest W; Stoffels P
    AIDS; 1996 May; 10(5):F1-7. PubMed ID: 8724034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy.
    Sei S; Stewart SK; Farley M; Mueller BU; Lane JR; Robb ML; Brouwers P; Pizzo PA
    J Infect Dis; 1996 Dec; 174(6):1200-6. PubMed ID: 8940209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.
    Holodniy M; Katzenstein D; Mole L; Winters M; Merigan T
    J Infect Dis; 1996 Oct; 174(4):854-7. PubMed ID: 8843229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.